Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) EBITDA: 2009-2024

Historic EBITDA for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Dec 2024 value amounting to -$39.8 million.

  • Vanda Pharmaceuticals' EBITDA fell 187.31% to -$31.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$120.0 million, marking a year-over-year decrease of 227.67%. This contributed to the annual value of -$39.8 million for FY2024, which is 205.10% down from last year.
  • Per Vanda Pharmaceuticals' latest filing, its EBITDA stood at -$39.8 million for FY2024, which was down 205.10% from -$13.0 million recorded in FY2023.
  • In the past 5 years, Vanda Pharmaceuticals' EBITDA registered a high of $43.6 million during FY2021, and its lowest value of -$39.8 million during FY2024.
  • For the 3-year period, Vanda Pharmaceuticals' EBITDA averaged around -$15.1 million, with its median value being -$13.0 million (2023).
  • Its EBITDA has fluctuated over the past 5 years, first surged by 52.12% in 2021, then slumped by 272.70% in 2023.
  • Vanda Pharmaceuticals' EBITDA (Yearly) stood at $28.6 million in 2020, then surged by 52.12% to $43.6 million in 2021, then tumbled by 82.68% to $7.5 million in 2022, then slumped by 272.70% to -$13.0 million in 2023, then tumbled by 205.10% to -$39.8 million in 2024.